Venus Remedies is currently trading at Rs. 237.40, up by 1.60 points or 0.68% from its previous closing of Rs. 235.80 on the BSE.

The scrip opened at Rs. 236.55 and has touched a high and low of Rs. 255.00 and Rs. 230.00 respectively. So far 6141 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 302.00 on 17-Oct-2023 and a 52 week low of Rs. 145.00 on 08-Feb-2023.

Last one week high and low of the scrip stood at Rs. 269.00 and Rs. 230.00 respectively. The current market cap of the company is Rs. 321.21 crore.

The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.03% and 57.21% respectively.

Venus Remedies has achieved market authorization in the United Kingdom for Bleomycin 15,000 IU Powder for Solution for Injection/lnfusion by its German subsidiary, Venus Pharma GmbH. This remarkable milestone not only expands the pharma giant's global presence but also underscores its commitment to advancing cancer care with innovative solutions.

Bleomycin 15,000 IU is a potent medication that contains the active ingredient bleomycin sulfate. It belongs to a group of medicines known as cytostatjc drugs, specifically designed to combat cancer. This class of medications, often referred to as chemotherapy, is renowned for its effectiveness in targeting cancer cells and preventing their uncontrolled division. 

Its versatile applications include the treatment of certain types of squamous cell carcinomas in the head and neck, cervix and external genitalia. It also serves as a panacea in treating severe types of lymph node cancers, such as Hodgkin's disease and nan-Hodgkin's lymphoma of intermediate and high malignancy, testicular cancer, and fluid accumulation in the lungs, often associated with cancer.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.